Emmanuelle Charpentier is a French scientist and Nobel Laureate. Along with American biochemist Jennifer Doudna, they discovered a molecular tool known as clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9, Charpentier shared the 2020 Nobel Prize in Chemistry. In 2013 Charpentier co-founded CRISPR Therapeutics, a company that employed CRISPR methodology for gene therapy in humans, with operations in Cambridge, Massachusetts, and headquarters in Zug, Switzerland. In 2015, after a two-year stint at Hannover Medical School in Germany, Charpentier moved her laboratory to the Max Planck Institute. Charpentier was recognized with numerous honours and awards, including the Canada Gairdner International Award (2016) and the Kavli Prize in Nanoscience (2018). She was an elected member of the Royal Swedish Academy of Sciences (2015) and the European Academy of Sciences and Arts (2018).
Max Planck Institute of Infection Biology